Is e aillse a' phròstain an dàrna aillse as cumanta ann an fir air feadh an t-saoghail, le tuairmse de 1.276 millean cùis ùr air an aithris ann an 2018, a' riochdachadh 7.1% de na cùisean aillse uile ann an fir.
Tha ìre bàsmhorachd airson aillse prostate àrd cuideachd, le tuairmse de 37,005 bàs air feadh an t-saoghail ann an 2018.
Ach, tha an ìre bàis ag atharrachadh gu mòr a rèir na sgìre, le Afraga an Iar aig a bheil an còigeamh cunnart as àirde airson bàsmhorachd aillse prostate san t-saoghal, agus Nigeria leis an àireamh-sluaigh agus an eaconamaidh as motha san sgìre seo.
Ann an Nigeria, is e aillse a' phròstain an aillse as cumanta agus as marbhtach do dh'fhir, le tuairmse de 32.8 cùis agus 16.3 bàs gach 100,000 duine.
Tha seo nas motha na dùbailte na ìre bàis ann an Ameireaga a Tuath.
Tha lorg fadalach a 'ghalair, goireasan cuingealaichte airson sgrùdadh agus lorg, agus lughdachadh sgrìobhainnean agus aithris chùisean a' cur ris an ìre bàis àrd ann an Nigeria.
Anns na Stàitean Aonaichte,'s e aillse a' phròstain an dàrna adhbhar as cumanta airson bàs aillse ann an fir, le timcheall air 40,0000 duine a' bàsachadh bhon ghalar gach bliadhna.
Tha ìre bàis aillse prostate air a bhith a' crìonadh gu slaodach bho thoiseach nan 1990an, ach tha e fhathast na dragh slàinte cudromach.
San fharsaingeachd, tha aillse prostate na ghalar marbhtach, gu sònraichte ann an sgìrean le cothrom cuingealaichte air cùram meidigeach agus goireasan sgrùdaidh.
Ach, faodaidh lorg agus làimhseachadh tràth toraidhean a leasachadh gu mòr agus ìrean bàis a lughdachadh.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Àicheadh: meidigeach']
["Tha an làrach-lìn seo air a thoirt seachad airson adhbharan foghlaim agus fiosrachaidh a-mhàin agus chan eil e a' toirt seachad comhairle mheidigeach no seirbheisean proifeiseanta."]
["Cha bu chòir am fiosrachadh a chaidh a thoirt seachad a chleachdadh airson duilgheadas slàinte no galar a dhearbhadh no a làimhseachadh, agus bu chòir dhaibhsan a tha a'sireadh comhairle meidigeach pearsanta co-chomhairle a chumail ri lighiche-sprèidh."]
["Thoiribh fa-near gu bheil an lìon neural a tha a' cruthachadh fhreagairtean do na ceistean, gu sònraichte neo-chruinneasach nuair a thig e gu susbaint àireamhach. Mar eisimpleir, an àireamh de dhaoine a chaidh a dhearbhadh le galar sònraichte."]
["Faigh comhairle an dotair agad no solaraiche slàinte eile a tha airidh air comhairle a thaobh tinneas meidigeach. Na dì-meas comhairle meidigeach proifeiseanta no dàil ann a bhith ga shireadh air sgàth rudeigin a leugh thu air an làrach-lìn seo. Ma tha thu a'smaoineachadh gum faodadh èiginn meidigeach a bhith agad, cuir fòn gu 911 no rachaibh chun t-seòmar èiginn as fhaisge sa bhad. Chan eil dàimh dotair-euslainteach air a chruthachadh leis an làrach-lìn seo no a chleachdadh. Chan eil BioMedLib no a luchd-obrach, no neach sam bith a tha a' cur ris an làrach-lìn seo, a 'dèanamh riochdachaidhean sam bith, fosgailte no a' toirt a-steach, a thaobh an fhiosrachaidh a tha air a thoirt seachad an seo no a chleachdadh."]
['Àicheadh: còraichean']
["Tha Achd Dlighe-sgrìobhaidh na Mìle Bliadhna Didseatach 1998, 17 U.S.C. § 512 (an DMCA) a' toirt ath-chuinge do shealbhadairean dlighe-sgrìobhaidh a tha den bheachd gu bheil stuth a tha a' nochdadh air an eadar-lìon a' briseadh an còraichean fo lagh dlighe-sgrìobhaidh na SA. "]
["Ma tha thu a' creidsinn ann an deagh chreideamh gu bheil susbaint no stuth sam bith a tha ri fhaotainn a thaobh ar làrach-lìn no ar seirbheisean a' briseadh d' dlighe-sgrìobhaidh, faodaidh tu fhèin (no an riochdaire agad) fios a chur thugainn ag iarraidh gun tèid an susbaint no an stuth a thoirt air falbh, no gun tèid cothrom a chur air. "]
["Feumar sanasan a chur ann an sgrìobhadh tro phost-d (faic an roinn 'Contact' airson seòladh puist-d). "]
["Tha an DMCA ag iarraidh gum bi am fiosrachadh a leanas anns an fhios agad mu bhriseadh còraichean-sgrìobhaidh a thathar ag ràdh: (1) tuairisgeul air an obair fo chòraichean-sgrìobhaidh a tha fo chasaid briseadh; (2) tuairisgeul air an t-susbaint a thathar ag ràdh a tha a 'briseadh agus fiosrachadh gu leòr gus leigeil leinn an t-susbaint a lorg; (3) fiosrachadh conaltraidh dhut, a' toirt a-steach do sheòladh, àireamh fòn agus seòladh puist-d; (4) aithris bhuat gu bheil creideas math agad nach eil an t-susbaint san dòigh a tha gearan air a cheadachadh le sealbhadair a 'chòraichean-sgrìobhaidh, no an neach-ionaid aige, no le gnìomh lagha sam bith; "]
['(5) Dearbhadh agaibh, air a shoidhnigeadh fo pheanas mionnachaidh, gu bheil am fiosrachadh san fhiosrachadh ceart agus gu bheil ùghdarras agaibh na còraichean-sgrìobhaidh a thathar ag ràdh a chaidh a bhriseadh a chur an gnìomh; ']
['agus (6) ainm-sgrìobhte corporra no eileagtronaigeach an t-sealbhadair dlighe-sgrìobhaidh no neach a tha ùghdarraichte a bhith ag obair às leth an t-sealbhadair dlighe-sgrìobhaidh. ']
["Ma dh'fhailicheas tu air a' ghearan agad a dheasachadh, faodaidh e dàil a chur air mura cuir thu a-steach am fiosrachadh gu lèir gu h-àrd."]
['Cuir fios thugainn']
['Cuir post-d thugainn le ceist / moladh sam bith.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Mu dheidhinn']
["Bidh BioMedLib a' cleachdadh choimpiutairean fèin-ghluasadach (algorithms ionnsachaidh innealan) gus paidhrichean ceist is freagairt a chruthachadh."]
["Bidh sinn a' tòiseachadh le 35 millean foillseachadh bith-leigheis de PubMed/Medline. Cuideachd, duilleagan-lìn de RefinedWeb."]
